SCHEMBL220642

SCHEMBL220642

Cc1ccc(Br)nc1.[Zn]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189127 0.97
SCHEMBL29794266 0.95
Formic Acid SCHEMBL28260450 0.84 CCR1 (0.43)
Formic Acid Methyl Ester SCHEMBL28260422 0.81 CCR1 (0.40)
SCHEMBL29843904 0.80
SCHEMBL1843031 0.80 CCR1 (0.39)
SCHEMBL29740319 0.71 CYP19A1 (0.44)
SCHEMBL172024 0.70
SCHEMBL31030 0.69
SCHEMBL16841 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215049-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2019-06-12 EP disclosed
US-20160362395-A1 INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS ROCHE PALO ALTO LLC (US) 2016-12-15 US disclosed
US-9440956-B2 Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2016-09-13 US disclosed
CN-102803245-B As P2X3And/or P2X2/3Antagonistic indole, indazole and benzimidazole aryl amides HOFFMANN LA ROCHE 2015-02-11 CN disclosed
EP-2445897-B1 NOVEL INDAZOLE ARYLAMIDES AS P2X3 AND/OR P2X2/3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-03-19 EP disclosed
US-20130267529-A1 INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS DILLON MICHAEL PATRICK (US) 2013-10-10 US disclosed
CN-103261198-A 2-arylimidazo[1,2-]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives JIANGSU HENGRUI MEDICINE CO 2013-08-21 CN disclosed
US-8481544-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-07-09 US disclosed
US-8476457-B2 Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2013-07-02 US disclosed
US-8389516-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-03-05 US disclosed
US-20100324070-A1 INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS DILLON MICHAEL PATRICK 2010-12-23 US disclosed
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2010-10-21 US disclosed
EP-2215049-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 EP disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US disclosed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed
US-20090197877-A1 Antibacterial Compositions PROLYSIS LTD. (GB) 2009-08-06 US disclosed
WO-2009058298-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 WO disclosed
EP-2034997-A1 ANTIBACTERIAL COMPOSITIONS Prolysis Limited (GB) 2009-03-18 EP disclosed
WO-2007148093-A1 ANTIBACTERIAL COMPOSITIONS PROLYSIS LTD. (GB) 2007-12-27 WO disclosed
CN-1617871-A Purine derivatives as purinergic receptor antagonists VERNALIS RES LTD (GB) 2005-05-18 CN disclosed